Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Raises Target Price to $34
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
BofA Adjusts Price Target on Catalyst Pharmaceuticals to $34 From $33
Catalyst Pharmaceuticals Inc. Stock Falls 4.5%, Underperforms Competitors
Santhera Pharmaceuticals Secures Funding for Duchenne Muscular Dystrophy Drug in UK
Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings Growth Rate Lags the 39% CAGR Delivered to Shareholders
Catalyst Says Health Canada Accepts New Drug Submission for Potential Neuromuscular Disease Treatment
Express News | Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of Agamree® New Drug Submission With Priority Review for Sub-Licensee Kye Pharmaceuticals
Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE New Drug Submission With Priority Review for Sub-Licensee Kye Pharmaceuticals
What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice?
Jim Cramer on Catalyst Pharmaceuticals (CPRX): 'That's My Kind of Stock!'
With 81% Ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), Institutional Investors Have a Lot Riding on the Business
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Investors Are Less Pessimistic Than Expected
Catalyst Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day
Truist Financial Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
Catalyst Pharmaceuticals(CPRX.US) Officer Sells US$4.89 Million in Common Stock